ZITADEL
10.6.2022 11:50:09 CEST | Business Wire | Press release
ZITADEL, innovator of a transformative identity management platform, announces $2.5M in seed funding led by Nexus Venture Partners. The funding will help ZITADEL provide developers with a much-needed open-source alternative for their identity management needs and evolve its solution, scale sales growth, and nurture the open-source community. The current market landscape consists of established but closed-source players, including Auth0, Okta, Firebase, AWS Cognito, and others.
ZITADEL’s founding vision was based on the creation of a streamlined, cloud-native identity management platform to speed time-to-market for software projects. Focused on the simplicity of integration, ready-to-use self-service features, a customizable and secure login with first-class support for passwordless authentication, and an API-first strategy, ZITADEL’s unique turnkey platform offers developers unprecedented flexibility.
Developers often spend countless hours creating, configuring, and operating complex authentication and authorization systems. ZITADEL, which is built mainly in the Go programming language, solves these problems with easy-to-use integrations in multiple languages and frameworks. This flexibility enables developers to utilize prebuilt features provided by ZITADEL to dramatically improve their productivity. In addition, ZITADEL’s capabilities address existing open-source projects which were not built for a cloud-native and serverless environment.
The ZITADEL team is working towards further enriching the solution’s enterprise-readiness. New capabilities include multi-tenancy, unlimited audit trails, improved ability to self-host, and support for serverless deployments, plus the potential to extend ZITADEL’s breadth with custom code created in WebAssembly. Combined with its cloud-native architecture, ZITADEL’s self-hosting capabilities allow privacy-focused customers to own and control their data by running a dedicated version. ZITADEL’s flexible model, with its span of smart efficiency enhancements, is already the go-to solution for numerous marquee enterprise customers.
The generous free tier of ZITADEL’s cloud-hosted offering allows anybody to create a ZITADEL instance in under five minutes—without a credit card. In its ongoing commitment to deliver GDPR support to its customers, ZITADEL Cloud also provides the capability to define the country or geopolitical region in which to store their data.
“Amidst today's complex software projects, ZITADEL provides a turnkey solution that allows developers to get started easily with a secure login, user management, multi-factor authentication, social logins, authorization management, and great APIs. With ZITADEL, we provide an important component to improve the overall security of a project while reducing your time-to-market,” said ZITADEL Co-Founder and CEO, Florian Forster.
“We’re delighted to break new ground partnering with Florian and the ZITADEL team, our first-ever investment in a Swiss company. We believe the future of digital identities is passwordless. ZITADEL takes a developer-first, open-source approach to solving identity management. Its simple and easy-to-integrate building blocks help developers build secure authentication into their applications without requiring deep in-house expertise and resource commitment.” said Abhishek Sharma, Managing Director at Nexus Venture Partners. “ZITADEL is the latest addition to the Nexus family of over a dozen marquee commercial open-source companies,” added Sharma.
About ZITADEL
ZITADEL is the modern open* alternative for Auth0, Firebase Auth, and AWS Cognito, as well as Keycloak, built for the container and serverless era. It provides customers a wide range of out-of-the-box features, including secure login, self-service, OpenID Connect, OAuth2.x, SAML2, branding, Passwordless with FIDO2, OTP, U2F, and an unlimited audit trail to improve the life of developers and developers. With its legal incorporation in Switzerland, ZITADEL is in the unique position of providing its cloud services even to customers with the strictest GDPR requirements. For more information visit https://zitadel.com , follow @zitadel on Twitter, or star the repository https://github.com/zitadel/zitadel on GitHub
About Nexus Venture Partners
Nexus Venture Partners is an early-stage venture capital firm partnering with extraordinary entrepreneurs to help build product-first software companies. With $2 billion under management, Nexus operates as one team across the U.S. and India. The Nexus portfolio includes Apollo.io, Aryaka, Clover Health, Delhivery, Druva, FingerprintJS, Hasura, H2O.ai, Infra Market, Kaltura, MinIO, Observe.ai, Postman, Pubmatic, Quizizz, Rancher, Rapido, Sibros, TileDB, Turtlemint, Unacademy, WhitehatJr, and Zepto. For more information, visit www.nexusvp.com or follow @nexusvp on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005526/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
